Analysts Maintain Strong Buy Consensus on Cullinan Management (CGEM) with Significant Upside Potential
核心洞察
Guggenheim (搜索) initiated coverage on Cullinan Management (搜索) with a Buy rating and a $30.00 price target, representing significant upside from the $11.96 closing price.
BTIG (搜索) analyst Julian Harrison maintained a Buy rating with a $38.00 price target, while JonesTrading (搜索) assigned a Buy rating with a $36.00 target.
The overall analyst consensus for Cullinan Management (搜索) is a Strong Buy, with an average price target of $31.50, implying a 167.4% upside.
Wall Street analysts are expressing strong optimism toward Cullinan Management (搜索) (NASDAQ: CGEM), with multiple firms initiating or reiterating Buy ratings and setting price targets that imply substantial upside from current trading levels.
Guggenheim (搜索) Initiates Coverage with Bullish Outlook
In a report released yesterday, Bradley Canino from Guggenheim (搜索) initiated coverage on Cullinan Management (搜索) with a Buy rating and a price target of $30.00. The company's shares closed last Friday at $11.96, suggesting a potential upside of approximately 151% based on Guggenheim's target. Canino, a 4-star analyst according to TipRanks, has an average return of 11.9% and a 43.5% success rate, covering the healthcare sector with a focus on stocks such as Black Diamond Therapeutics, Syndax Pharmaceuticals, and Olema Pharmaceuticals.
BTIG (搜索) and JonesTrading (搜索) Reinforce Positive Sentiment
BTIG (搜索) analyst Julian Harrison maintained a Buy rating on Cullinan Management (搜索) with an even more aggressive price target of $38.00. Harrison, a 5-star analyst with an average return of 41.7% and a 52.1% success rate, covers healthcare stocks including MoonLake Immunotherapeutics, Connect Biopharma Holdings, and Mereo Biopharma Group Plc.
In a separate report issued on January 23, JonesTrading (搜索) also assigned a Buy rating to the stock with a $36.00 price target. Additionally, Stifel Nicolaus (搜索) maintained a Buy rating with a $28.00 price target in a report issued on May 25.
Strong Buy Consensus with Triple-Digit Upside
The overall analyst consensus on Cullinan Management (搜索) stands at Strong Buy, with an average price target of $31.50, representing a 167.4% upside from recent trading levels. The price targets from various firms range from $28.00 to $38.00, reflecting broad confidence in the company's pipeline and strategic direction.
Cullinan Management (搜索) is a clinical-stage biopharmaceutical company advancing a diversified pipeline of targeted oncology and immunology therapies. The strong analyst support underscores Wall Street's conviction in the company's ability to execute on its clinical development programs and deliver value to shareholders.